Skip to main content

Mastocytosis

1
Pipeline Programs
3
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Leo Pharma
Leo PharmaDenmark - Ballerup
1 program
1
CromoglicatePhase 21 trial
Active Trials
NCT01701843Terminated7Est. Feb 2013
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
5 programs
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and FlushingN/A1 trial
Cause and Natural Course of Pediatric-Onset MastocytosisN/A1 trial
Characteristics of Mast Cells in MastocytosisN/A1 trial
Study of Factors Regulating Mast Cell ProliferationN/A1 trial
Study of Mast Cell PrecursorsN/A1 trial
Active Trials
NCT00047918Completed100Est. Aug 2004
NCT00050193Completed103Est. Mar 2014
NCT00001356Completed300Est. May 2002
+2 more trials
Blueprint Medicines
Blueprint MedicinesMA - Cambridge
1 program
Mast Cell Connect: A Registry for Patients With MastocytosisN/A1 trial
Active Trials
NCT02620254Completed743Est. Jan 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Leo PharmaCromoglicate
Blueprint MedicinesMast Cell Connect: A Registry for Patients With Mastocytosis
Allergy TherapeuticsCause and Natural Course of Pediatric-Onset Mastocytosis
Allergy TherapeuticsBlood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
Allergy TherapeuticsStudy of Factors Regulating Mast Cell Proliferation
Allergy TherapeuticsStudy of Mast Cell Precursors
Allergy TherapeuticsCharacteristics of Mast Cells in Mastocytosis

Clinical Trials (7)

Total enrollment: 2,055 patients across 7 trials

NCT01701843Leo PharmaCromoglicate

Cromoglicate in Mastocytosis

Start: Oct 2012Est. completion: Feb 20137 patients
Phase 2Terminated
NCT02620254Blueprint MedicinesMast Cell Connect: A Registry for Patients With Mastocytosis

Mast Cell Connect: A Registry for Patients With Mastocytosis

Start: Nov 2015Est. completion: Jan 2021743 patients
N/ACompleted
NCT00050193Allergy TherapeuticsCause and Natural Course of Pediatric-Onset Mastocytosis

Cause and Natural Course of Pediatric-Onset Mastocytosis

Start: Nov 2002Est. completion: Mar 2014103 patients
N/ACompleted
NCT00047918Allergy TherapeuticsBlood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing

Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing

Start: Oct 2002Est. completion: Aug 2004100 patients
N/ACompleted
NCT00044122Allergy TherapeuticsStudy of Factors Regulating Mast Cell Proliferation

Study of Factors Regulating Mast Cell Proliferation

Start: Sep 2002600 patients
N/ARecruiting
NCT00001756Allergy TherapeuticsStudy of Mast Cell Precursors

Study of Mast Cell Precursors

Start: Dec 1997Est. completion: Nov 2022202 patients
N/ACompleted
NCT00001356Allergy TherapeuticsCharacteristics of Mast Cells in Mastocytosis

Characteristics of Mast Cells in Mastocytosis

Start: May 1993Est. completion: May 2002300 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 2,055 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.